Cancer Stories: The Art of Oncology

The award-winning podcast JCO Cancer Stories: The Art of Oncology invites you on an intimate journey with heartfelt narratives, poignant reflections, and thoughtful dialogues. Hosted by Dr. Mikkael Sekeres, the podcast explores the hidden emotions, intense experiences, and resilient strength of clinicians, caregivers, and those living with cancer. This podcast is essential for nourishing the "art" behind the science of oncology.

  1. The Power of "I Don't Know": Why Admitting Uncertainty is an Oncologist's Greatest Strength

    24 Mar

    The Power of "I Don't Know": Why Admitting Uncertainty is an Oncologist's Greatest Strength

    Listen to JCO's Art of Oncology article, "The Power of "I Don't Know" by Dr. Sondos Zayed, who is a radiation oncologist at The Ottawa Hospital and an assistant professor at the University of Ottawa, Canada. The article is followed by an interview with Zayed and host Dr. Mikkael Sekeres. Dr Zayed shares a reflection on the unexpected power of saying "I don't know," and how honest uncertainty can deepen trust, guide care and create space for what truly matters in oncology. TRANSCRIPT Narrator: The Power of "I Don't Know", Sondos, Zayed, MD, MPH, FRCPC  Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. Joining us today is Dr. Sondos Zayed, a radiation oncologist at the Ottawa Hospital and Assistant Professor at the University of Ottawa, Canada, to discuss her Journal of Clinical Oncology article, "The Power of I Don't Know." At the time of this recording, our guest has no disclosures. She and I have agreed to address each other by first names. Sondos, thank you for contributing to the Journal of Clinical Oncology, and what a pleasure it is to have you join us to discuss your article. Dr. Sondos Zayed: Thank you so much for having me. It's a privilege. Mikkael Sekeres: Can you tell us a little bit about yourself? Where are you from? And walk us through your career up to this point. Dr. Sondos Zayed: Yeah, oh my goodness. So it seems like such a long road and yet so many years left in my career, hopefully. You know, I'm Canadian, and I had the opportunity to grow up in Montreal, which was wonderful, and I went to McGill Medical School, and then after that pursued Radiation Oncology Residency at Western University. And following that I did a fellowship specializing in GI and CNS malignancies with MR-Linac technology in Toronto, and eventually landed in Ottawa, where right now I'm a radiation oncologist treating GI and CNS malignancies and an Assistant Professor at the University of Ottawa. Mikkael Sekeres: That's fantastic. How far are you out of training? Dr. Sondos Zayed: Well, this would be officially my second year essentially as an independent radiation oncologist. Mikkael Sekeres: Wonderful. And I'm curious, what drew you to radiation oncology? Dr. Sondos Zayed: I always say that it was meant to be. And the reason being, when I was in medical school at McGill, they parachuted us out into very niche specialties that we wouldn't otherwise have exposure to. And essentially the way that they would do that is they'd send us an email and say, you know, "Show up at this place, at this location. Here's attached a PowerPoint, just review it before you go." And I get this email and the PowerPoint is talking about, you know, photons and electrons, linear accelerators. And I'm like, "I have no idea what's going on. This is so confusing." I thought I was in medicine. And so I do follow the instructions and I was so lucky that I had such a wonderful supervisor, and he showed me the machines and I saw the coolest cases that day, and it was just such a wonderful experience and the most captivating. And so I just kept on wanting to go back. And the rest is literally history. The really, really fascinating thing about radiation oncology is that it's the mix of physics, it's a mix of like technology, and at the same time there's the medicine and the clinical aspect of it. And there's obviously the privilege to be able to support patients on their most vulnerable journeys with their cancer diagnosis and treatment, et cetera. And so it's a mix of the most interesting things all around and I felt like the best fit for me. Mikkael Sekeres: Well, your passion for it is absolutely palpable. It's really fun to hear the excitement in your voice. Isn't it interesting how one mentor can make the difference in the career path we choose? Dr. Sondos Zayed: Absolutely. Never underestimate the impact they can have on any single trainee at any point in time. It really does turn things around for many people, and it can inspire them to pursue something that they would have never thought of pursuing before. Mikkael Sekeres: I had a very similar experience. It was during fellowship that my very first month of fellowship I was placed on the leukemia service with Rich Stone at Dana-Farber, and I never turned back. He was such a fabulous mentor. I couldn't imagine doing anything else with my career. You write this piece. We loved this piece when you submitted it, myself and the editorial staff. And you write it from the perspective of someone who has recently finished fellowship, which you have. And you write in particular that- this one quote, "During my first year as an attending, I had braced for the steep learning curve, the finality of being the decision maker, the quiet hours at night when treatment decisions still played in my head. What I hadn't prepared for was the weight of uncertainty." It's a great line. So now that you're on the other side of training, what do you think could have prepared you better for the weight of uncertainty? Dr. Sondos Zayed: I had such wonderful mentors throughout my training, and so they were fantastic and I learned so much from them, but sometimes it just took having to be the final decision maker for me not to have to have the security of somebody to just turn back to immediately after a patient encounter, for example, and be like, "Oh, my supervisor can answer this question," or, "Here are my thoughts, but my attending can also join in the discussion," or give their thoughts as well. So that sort of cushion is no longer there. And so when I'm in the room by myself making those decisions with patients, nothing can really prepare you for that. You just have to go in and then do it yourself. Mikkael Sekeres: There is a safety net to training by design and thank God there is, right? Where we can always turn to somebody more experienced than us to answer those hard questions or to know what to do. And that's what's pulled out from under us when we become attendings, when we become the final pathway, when people suddenly turn to us and say, "Okay, what are we going to do here?" or, "What's the answer?" Did anybody during your training model "I don't know"? So did you see your own attendings say "I don't know" to patients and see how that played out? Dr. Sondos Zayed: Not as much, and I think there's a culture in medicine where when people walk into that room, they're hoping that you have all the answers, and you don't want to disappoint them. And so sometimes what we do is we rely on like the evidence and the data and the numbers that are in the literature to answer questions that the patient is asking in an absolute way but we answer it in a probability or a percentage or, "Most likely this will happen," or, "These are the potential, you know, this is the median overall survival," or, "Progression-free survival," or, "This percentage of people have this toxicity," for example. And so it's easy for us to fall back on that cushion of, "These are the numbers and the evidence." And that's what I saw modeled most frequently. But when I started practicing as an attending, what I realized is that when a patient comes in and they sit in front of you, they ask, "How long am I going to live?" What they're asking about is how long they specifically are going to live and not what the median survival in X study is telling us that that's how long they most likely would live, just as an example. And so what I had to do, when I'm speaking to patients, I kind of separate those two concepts where I start with, "I don't know, because I don't have a crystal ball, and your circumstances and how you respond to treatment is something that I can't predict before anything has started. And it's it's just I really don't know. But what I can say is on average in this study, this is what we see, and there's a 95% confidence interval, and most people fall within that." And so I separate their immediate outcome with the data that we have. So that- because sometimes when I say, "Oh, your median survival is one year," they hear, "I'm going to only live for one year." And then you always have these patients that come through and be like, "You know, they told me I only had six months to live, but here I am two years later." And really it is again, we live in a world of probabilities and confidence intervals, but for the patients themselves, this is their life. Mikkael Sekeres: Yeah. One of the aspects of your essay that I really liked is the title, "The Power of 'I Don't Know'" because saying, "I don't know," actually does have some power to it. And I've seen this demonstrated in a couple of different ways. I had a boss once who we'd all be in a meeting, and someone would ask a question, and the boss would say, "I don't know." And he said it in a way where one reaction from other people in the meeting could have been, "Oh, how could he be such an idiot and not know the answer to this?" But what wound up happening is people reacted to it by saying, "Gee, if he doesn't know, then it's okay that I don't know also. And maybe if he doesn't know, that means that maybe I thought I knew, but maybe I really don't know as well as I should." And it makes you kind of redouble your efforts to understand whatever's being communicated in the meeting. So I always thought that there was this power in saying, "I don't know," in meetings, but you bring up the power of "I don't know" in patient interactions. So tell me what is the power in saying, "I don't know," to a patient? What is it that that conveys to a patient and how does that affect the relationship that you have with your patients?

    24 min
  2. When Cancer Becomes a Headline: Reflections from the Clinic

    10 Mar

    When Cancer Becomes a Headline: Reflections from the Clinic

    Listen to JCO OP's Art of Oncology Practice article, "When Cancer Becomes a Headline: Reflections from the Clinic" by Dr. Carlos Stecca. The article is followed by an interview with Stecca and host Dr. Mikkael Sekeres. Dr Stecca reflects on the impact of the public illness and death of Brazilian singer and actress Preta Gil on his patients with colorectal cancer and on his own practice as a medical oncologist. TRANSCRIPT Narrator: When Cancer Becomes a Headline: Reflections from the Clinic, by Carlos Stecca, MD Dr. Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a pleasure it is today to have Dr. Carlos Stecca, a medical oncologist at Evangelical Mackenzie University Hospital, to discuss his JCO Oncology Practice article, "When Cancer Becomes a Headline: Reflections From the Clinic". Dr. Stecca and I have agreed to call each other by first names. Carlos, thank you for contributing to JCO Oncology Practice and for joining us today to discuss your article. Dr. Carlos Stecca: So great to be here. Thank you so much for having me. Dr. Mikkael Sekeres: I wonder if we could start off by asking you to tell us about yourself. Where are you from and what led you to this point in your career? Dr. Carlos Stecca: So I am Brazilian. I was born in Brazil in a small town in the south of Brazil, and I did my medical training all in Brazil. So I did medical school here, internal medicine, and medical oncology. My residency period ended in early 2018. I did my residency at the AC Camargo Cancer Center, which is in Sao Paulo. And then right after that, I moved closer to my parents to start my journey as a medical oncologist. And I stayed here in the south for two more years. And then I was lucky enough to be accepted for a clinical research fellowship in genitourinary malignancies at the Princess Margaret Cancer Center. And I had the pleasure to work with Dr. Kala Sridhar for two years. So this was during the pandemic, so 2020, 2021. And then right after that, I moved back to Brazil. And I've been here for the past four years working as a medical oncologist specialized in genitourinary malignancies. But also, well, unfortunately here in Brazil most of us cannot do only one site, so we have to do a little bit more, so I'm doing gynae and GI as well. And in a few days, I'm moving back to Canada. I was lucky enough again to be accepted for a position at the University of British Columbia, so I'm moving in a few days. Dr. Mikkael Sekeres: Oh, my word. We caught you just in time then. Dr. Carlos Stecca: Yeah, yeah. I'm moving in four days now. Dr. Mikkael Sekeres: I can't imagine what it's like to be going between those extremes of weather from Canada down to Brazil. Did your teeth crack when you did that? Dr. Carlos Stecca: Something like that. Yeah, it was like, I moved in December. So in December we have summer here in Brazil, and it was like 35, 40 degrees Celsius when I left Brazil at the airport. And when I arrived, it was close to minus 20 when I went to Toronto. Yeah. Dr. Mikkael Sekeres: Oh, my word. Dr. Carlos Stecca: It was rough. Dr. Mikkael Sekeres: Well, those of us who live at or near the Southern Hemisphere, I will tell you, I've started to wear puffy jackets and snow caps when it drops into the 60s. Good luck with reacclimating to Canada. I wonder if we could talk a little bit about the story that sparked this terrific essay. It was so interesting. The Brazilian singer and actress Preta Gil died of rectal cancer in July of 2025 at the age of 50. And she went public with her diagnosis. What is it that she communicated to the public about colorectal cancer? Dr. Carlos Stecca: So she was very open about her diagnosis since the beginning. So this was very interesting. She is very famous here. She had tons of followers on Instagram and social media, and she was very outspoken about her diagnosis since the first beginning. So she was diagnosed with an early stage disease, and she did a great job raising awareness for this condition, for colorectal cancer. She had a beautiful journey discussing the specifics of her case. Dr. Mikkael Sekeres: So she talked both about her diagnosis and some of the treatments she was undergoing, but also about symptoms of cancer, right? Dr. Carlos Stecca: She really engaged in this discussion about her diagnosis and how she found out about her cancer. So rectal bleeding, this was disclosed in her stories on Instagram, and so she was very open about this. And it really helped people understand the condition, and it really increased the number of screening tests that Brazilians were doing. And of course, we saw this increasing uptake of the screening tests, which was amazing. Dr. Mikkael Sekeres: In a way, I think she did a real public service, I think, both for early detection of colorectal cancer with symptoms, also for screening, so asymptomatic people who would undergo colonoscopies, and also demystified a little bit the treatment of colorectal cancer. In the US, we saw a similar phenomenon when the actor Chad Boseman of Black Panther movie franchise fame died of colorectal cancer in 2020 at the age of 43. These deaths have also sparked an international conversation about cancer in younger adults. Are you seeing that in your clinic? Dr. Carlos Stecca: Yes, definitely. We're seeing many more cases of cancer diagnosed in the younger population, right? So yeah, this discussion was very important to have, not only because the screening tests increased in patients after the age of 50 years old without any symptoms, but also raised awareness for those symptoms that should trigger the proper investigation. Dr. Mikkael Sekeres: I wonder if you could speculate a little bit about why it is that we're seeing more cancer in younger adults. Do you think it has anything to do, for example, with diet and people eating more ultra-processed foods? Is it a phenomenon? I've even heard people talk about microplastics and whether that could be contributing. Also, recently, there was an article that came out that speculated that while we're seeing more cancers in younger adults, we're not seeing more deaths in younger adults, so we may just be picking these up earlier as more people are going to be screened or for additional testing at a younger age. Dr. Carlos Stecca: Yeah, I think so. I think this is definitely the case. I think younger adults are eating more processed foods, and we know that this is an obvious risk factor for colorectal cancer and other cancers as well. And maybe obesity as well, we are seeing this as a pandemic now in the world, right? So we are seeing this especially in developing countries. And here in Brazil, of course, we are seeing this as a phenomenon. Dr. Mikkael Sekeres: It's so fascinating. I feel like we won't really know the answer about the uptick in cancers in younger adults for years until some of the data settle out, including the data about people during the COVID pandemic not going for screening and testing as often and whether we're now starting to see the downstream effects of that. Dr. Carlos Stecca: For sure, I think this is- well, during the pandemic I was in Canada, but shortly after the pandemic was coming to an end, I came back to Brazil, and I saw that. I saw that a lot of patients came to the clinic with more advanced cancers because they missed those opportunities of being seen by a physician during the pandemic, because of course, for obvious reasons, people were not coming to the clinic. And we saw that, a huge number of patients being diagnosed with late-stage disease because of that. Dr. Mikkael Sekeres: It's fascinating. There's a named phenomenon called the Angelina Jolie effect. I don't know if you remember following the actress's 2013 opinion piece about genetic testing for hereditary cancers such as BRCA1 and following her prophylactic mastectomy. She is a carrier of a mutation. There was a wave of testing that occurred thereafter. So some good can come from celebrities going public with their cancer diagnosis. Dr. Carlos Stecca: Oh, definitely, definitely. I think that more good can come from their diagnosis and them being verbal about this than the downsides. Of course, the positive side of it is definitely outweighing the negative effect. Dr. Mikkael Sekeres: You write a really thoughtful essay. You mention downsides, and there can be some downsides. One of the things you wrote in your essay was, "Yet for others already living with colorectal cancer, the same story had the opposite effect. Instead of empowerment, it fueled anxiety, guilt, and resignation. Some patients grew silent, fearing their treatment was futile as they compared themselves to a celebrity who had access to the best hospitals, specialists, and resources, and still passed away. Others questioned why they had not caught their cancer earlier, internalizing blame." Can you talk a little bit more about some of the unintended consequences of a celebrity who goes public with his or her cancer diagnosis? Dr. Carlos Stecca: That was exactly it, right? I was witnessing this in my clinic. I work in a public hospital here, and I would see those patients coming to me and voicing their concerns about their diagnosis, colorectal cancer, that was now in the spotlight because of that famous person that battled with colorectal cancer and unfortunately passed away after two years of starting her journey. And that was something quite difficult for the patients because, as you mentioned, and as I wrote in the text, some of those patients were in the public system and they were comparing themselves, comparing th

    25 min

About

The award-winning podcast JCO Cancer Stories: The Art of Oncology invites you on an intimate journey with heartfelt narratives, poignant reflections, and thoughtful dialogues. Hosted by Dr. Mikkael Sekeres, the podcast explores the hidden emotions, intense experiences, and resilient strength of clinicians, caregivers, and those living with cancer. This podcast is essential for nourishing the "art" behind the science of oncology.

More From ASCO Podcasts

You Might Also Like